Navigation Links
Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Postherpetic Neuralgia
Date:9/19/2011

ve seen in our earlier clinical and pre-clinical studies."

Dr Milton Raff (Christiaan Barnard Memorial Hospital, Cape Town, South Africa), Principal Investigator for the Study, said: "Current treatments for postherpetic neuralgia are effective in some patients but a significant proportion either don't respond to therapy and are left with debilitating symptoms or suffer significant side effects. EMA401 offers an entirely novel approach to the treatment of the condition and could represent a valuable new option in an area where there is a clear need for new medicines."

In addition to PHN, Spinifex's clinical program for EMA401 will include studies in other neuropathic pain indications including pain and hypersensitivity in peripheral nerve injury patients, and pain and hypersensitivity in cancer chemotherapy patients. The market for neuropathic pain treatments is expected to continue to increase and is projected to reach US$6.2 billion by 2017. Despite this growth, current therapy needs to be improved as a significant proportion of neuropathic pain patients don't respond to current therapy and these treatments have dose-limiting side effects. As a result, EMA401 is being developed as a potential first-in-class oral treatment for neuropathic pain and related symptoms without central nervous system side effects.

Spinifex Pharmaceuticals

Spinifex Pharmaceuticals is an Australian biotechnology company developing new drug candidates for the treatment and management of pain.

Established in 2005 and based in Melbourne, Spinifex has applied its world-class drug development capabilities to advance product candidates. Its lead product EMA401 is under development as a potential first-in-class oral treatment for neuropathic pain and related symptoms without CNS side effects. Spinifex's Phase 2 program for EMA401 will include clinical trials in a number of neuropathic pain conditions. Spinifex investors are GBS Venture Partners, Brandon Capi
'/>"/>

SOURCE Spiniflex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... last Thursday, August 14, 2014, has closed.  The three-year ... at $7.30 per share of common stock.  The investors ... purchase up to an additional 30% of these notes ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3
... Epiphany Biosciences announced,today, the initiation of a ... treatment and management of acute infectious,mononucleosis. Currently, there ... debilitating condition or any other disease caused by,the ... broad spectrum of anti-viral activity,including inhibition of viral ...
... SAN FRANCISCO, Calif., Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... (NYSE: PFE ), has begun a Phase 1 ... syk kinase inhibitor, R343,for the treatment of allergic asthma. ... Under the terms of the companies, 2005 collaboration ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Get the report here: ... presents “Deal Drivers 2014 Half Year Report for the ... activity in both North and South America, with targeted ... Merrill DataSite     , Merrill DataSite is a secure ... due diligence process by providing a highly efficient and ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Understanding ... governmental and physician stakeholders networks impacting the launch ... America, US, Canada, and Emerging Markets. , This ... Experts’ perspectives on stakeholder management needs for the ... immunotherapy and targeted therapy investigational agents that are ...
(Date:8/20/2014)... Angeles, CA (PRWEB) August 20, 2014 ... it is bringing on Wrench Advisors as a ... tasks including international large accounts. , As Wrench ... sales consultants can help your organization plan and ... executives and global distribution channels. Our experience developing ...
(Date:8/20/2014)... Beach, Florida (PRWEB) August 20, 2014 ... Florida, with the help of their experienced surgeons trained ... of patients to regain their lost or inaccurate vision. ... for performing Lasik surgery is making it possible for ... aging disease which occurs normally in people in the ...
Breaking Medicine News(10 mins):Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Register to Download Merrill DataSite's Report: Deal Drivers 2014 Half Year Report for the Americas 2Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... August 2, 2009 The world,s top lung cancer ... in San Francisco, CA for the 13th World Conference ... for the Study of Lung Cancer (IASLC). Prevention and ... lung cancer remains one of the hardest cancers to ...
... , , , ... around the world are turning to cosmetic surgery in increasing numbers, ... "moobs" ("man boobs".) , , Male cosmetic surgery ... countries where the stigma attached to male cosmetic surgery has all ...
... , MINNEAPOLIS, July 28 Employees ... boots this week as the cooperative put in place a new ... to execute a voluntary recall of instant nonfat dried milk, whey ... new protocols for the dry ingredients production area in preparation for ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... 1, 2009 The world,s top lung cancer specialists, ... San Francisco, CA for the 13th World Conference on ... the Study of Lung Cancer (IASLC). According to a ... therapies, as first-line treatment, have the potential to slow ...
... ... its entry into the interventional radiology marketplace with the nationwide launch of its new ... ... entry into the interventional radiology marketplace with the nationwide launch of its new ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Men Around the World Seek Cosmetic Surgery 2Health News:Plainview Milk Products Cooperative Implements New Employee Boot Policy 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:New DrainEx(TM) Catheter Simplifies Insertion and Replacement 2
... 1100RS Spectrophotometers are simple, ... for use in many ... educational, clinical, industrial and ... COD vial holders, Windows ...
Spectra 2000 Digital Spectrophotometer is designed for quantitative and qualitative analysis in visible range from 320 nm to 1020 nm....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... Darkfield Quebec Colony Counter allows the user ... choice of models allows for digital counting or ... over the standard lens increasing magnification to 3.0X. ... lens to be raised or lowered. The lens ...
Medicine Products: